Westerkirk Capital Inc. Takes $669,000 Position in Amgen Inc. $AMGN

Westerkirk Capital Inc. acquired a new position in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,370 shares of the medical research company’s stock, valued at approximately $669,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the second quarter worth $27,000. Evelyn Partners Investment Management LLP purchased a new position in Amgen during the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen during the second quarter valued at about $32,000. Quaker Wealth Management LLC lifted its holdings in shares of Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after buying an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC bought a new position in shares of Amgen in the third quarter valued at approximately $34,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $374.75 on Monday. The company has a 50-day simple moving average of $343.21 and a two-hundred day simple moving average of $316.54. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12. The firm has a market cap of $202.02 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 3.71 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 70.84%.

Analyst Ratings Changes

A number of research firms recently weighed in on AMGN. Deutsche Bank Aktiengesellschaft upped their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Daiwa Securities Group increased their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Barclays initiated coverage on Amgen in a research report on Friday. They set an “equal weight” rating and a $350.00 price target for the company. Finally, UBS Group raised their target price on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.